Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vivo |
Following SP injection, substance P(1–7) is shown to develop locally in the nigra and to operate as a very powerful antagonist against the reactions elicited by SP. It has been suggested that Substance P(1–7) regulates SP activities endogenously[1]. When Substance P(1-7) (1.0-4.0 pM) is injected concurrently with SP or SP(5-11) (0.1 nM), the unpleasant behaviors caused by SP or SP(5-11) are greatly reduced. These findings suggest that endogenously produced SP(1–7) may be able to influence how SP or SP(5–11) behave in the spinal cord[2].
|
---|---|
References |
Molecular Formula |
C43H66F3N13O12
|
---|---|
Molecular Weight |
1014.06
|
Exact Mass |
1013.49
|
CAS # |
2828433-22-1
|
Related CAS # |
Substance P(1-7);68060-49-1
|
PubChem CID |
134694976
|
Appearance |
White to off-white solid powder
|
Hydrogen Bond Donor Count |
12
|
Hydrogen Bond Acceptor Count |
18
|
Rotatable Bond Count |
27
|
Heavy Atom Count |
71
|
Complexity |
1760
|
Defined Atom Stereocenter Count |
7
|
SMILES |
C(N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](C(=O)O)CC1C=CC=CC=1)(=O)[C@H](CCCCN)NC([C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)=O.C(F)(F)(F)C(=O)O
|
InChi Key |
NGJNGAVSGJSPNQ-OSSAIMHMSA-N
|
InChi Code |
InChI=1S/C41H65N13O10.C2HF3O2/c42-19-5-4-12-28(51-37(60)30-13-7-21-53(30)38(61)25(43)11-6-20-48-41(46)47)39(62)54-22-8-14-31(54)36(59)50-27(16-18-33(45)56)34(57)49-26(15-17-32(44)55)35(58)52-29(40(63)64)23-24-9-2-1-3-10-24;3-2(4,5)1(6)7/h1-3,9-10,25-31H,4-8,11-23,42-43H2,(H2,44,55)(H2,45,56)(H,49,57)(H,50,59)(H,51,60)(H,52,58)(H,63,64)(H4,46,47,48);(H,6,7)/t25-,26-,27-,28-,29-,30-,31-;/m0./s1
|
Chemical Name |
(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoic acid;2,2,2-trifluoroacetic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: 50 mg/mL (49.31 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (98.61 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.9861 mL | 4.9307 mL | 9.8613 mL | |
5 mM | 0.1972 mL | 0.9861 mL | 1.9723 mL | |
10 mM | 0.0986 mL | 0.4931 mL | 0.9861 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.